维普中文期刊产品整合服务
25篇 您的检索式:作者名="Paola Loria"
    题名 作者 年代 出处 被引量
1Risk of cardiovascular,cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has emerged as a public health problem of epidemic proportions worldwide.Accumulating clinical and epidemiological evidence indicates that NAFLD is not only associated with liver-related morbidity and mortality but also with an increased risk of coronary heart disease(CHD),abnormalities of cardiac function and structure(e.g.,left ventricular dysfunction and hypertrophy,and heart failure),valvular heart disease(e.g.,aortic valve sclerosis)and arrhythmias(e.g.,atrial fibrillation).Experimental evidence suggests that NAFLD itself,especially in its more severe forms,exacerbates systemic/hepatic insulin resistance,causes atherogenic dyslipidemia,and releases a variety of pro-inflammatory,pro-coagulant and pro-fibrogenic mediators that may play important roles in the pathophysiology of cardiac and arrhythmic complications.Collectively,these findings suggest that patients with NAFLD may benefit from more intensive surveillance and early treatment interventions to decrease the risk for CHD and other cardiac/arrhythmic complications.The purpose of this clinical review is to summarize the rapidly expanding body of evidence that supports a strong association between NAFLD and cardiovascular,cardiac and arrhythmic complications,to briefly examine the putative biological mechanisms underlying this association,and to discuss some of the current treatment options that may influence both NAFLD and its related cardiac and arrhythmic complications.Stefano Ballestri Amedeo Lonardo Stefano Bonapace Christopher D Byrne Paola Loria Giovanni Targher 2014World Journal of Gastroenterology2014,20,7:55
2Incidence of gallstone disease in Italy:Results from a multicenter,population-based Italian study (the MICOL project)显示文摘AIM:To evaluate gallstone incidence and risk factors in a large population-based study. METHODS: Gallstone incidence and risk factors, were evaluated by structured questionnaire and physical examination, respectively, in 9611 of 11 109 (86.5%) subjects who were gallstone-free at the cross-sectional study. RESULTS: Six centers throughout Italy enrolled 9611 subjects (5477 males, 4134 females, aged 30-79 years), 9517 of whom were included into analysis: 424 subjects (4.4%) had gallstones and 61 (0.6%) had been cholecystectomized yielding a cumulative incidence of 0.67% per year (0.66% in males, 0.81% in females). Increasing age, a high body mass index (BMI), a history of diabetes, peptic ulcer and angina, and low cholesterol and high triglyceride levels were identifi ed as risk factors in men while, in females, the only risk factors were increasing age and a high BMI.Increasing age and pain in the right hypocondrium in men and increasing age in females were identifi ed as predictors of gallstones. Pain in the epigastrium/ right hypocondrium was the only symptom related to gallstones; furthermore, some characteristics of pain (forcing to rest, not relieved by bowel movements) were significantly associated with gallstones. No correlation was found between gallstone characteristics and clinical manifestations, while increasing age in men and increasing age and BMI in females were predictors of pain. CONCLUSION:Increasing age and BMI represent true risk factors for gallstone disease (GD); pain in the right hypocondrium and/or epigastrium is confi rmed as the only symptom related to gallstones.Davide Festi Ada Dormi Simona Capodicasa Tommaso Staniscia Adolfo F Attili Paola Loria Paolo Pazzi Giuseppe Mazzella Claudia Sama Enrico Roda Antonio Colecchia 2008World Journal of Gastroenterology2008,14,34:23
3Nonalcoholic fatty liver disease and aging: Epidemiology to management显示文摘Nonalcoholic fatty liver disease(NAFLD) is common in the elderly, in whom it carries a more substantial burden of hepatic(nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma) and extra-hepatic manifestations and complications(cardiovascular disease, extrahepatic neoplasms) than in younger age groups. Therefore, proper identification and management of this condition is a major task for clinical geriatricians and geriatric hepatologists. In this paper, the epidemiology and pathophysiology of this condition are reviewed, and a full discussion of the link between NAFLD and the aspects that are peculiar to elderly individuals is provided; these aspects include frailty, multimorbidity, polypharmacy and dementia. The proper treatment strategy will have to consider the peculiarities of geriatric patients, so a multidisciplinary approach is mandatory. Non-pharmacological treatment(diet and physical exercise) has to be tailored individually considering the physical limitations of most elderly people and the need for an adequate caloric supply. Similarly, the choice of drug treatment must carefully balance the benefits and risks in terms of adverse events and pharmacological interactions in the common context of both multiple health conditions and polypharmacy. In conclusion, further epidemiological and pathophysiological insight is warranted. More accurate understanding of the molecular mechanisms of geriatric NAFLD will help in identifying the most appropriate diagnostic and therapeutic approach for individual elderly patients.Marco Bertolotti Amedeo Lonardo Chiara Mussi Enrica Baldelli Elisa Pellegrini Stefano Ballestri Dante Romagnoli Paola Loria 2014World Journal of Gastroenterology2014,20,39:15
4Fatty liver,carotid disease and gallstones:A study of age-related associations显示文摘AIM: To evaluate carotid intima-media thickening (IMT) and plaques, gallstone disease (GD) and fatty liver (FL) as a function of age. METHODS: In 449 subjects, FL and carotid disease were assessed ultrasonographically. In a subgroup of 65/449 patients with non-alcoholic fatty liver disease (NAFLD), carotid disease, GD and associated factors were determined. RESULTS: FL of unspecified etiology was more common in younger and GD in older individuals. FL subjects had an increased prevalence of IMT and a decreased prevalence of plaques and manifested carotid disease earlier. Plaques were more common in subjects with GD. Age was an independent predictor of carotid disease outcome and FL was a protective factor for plaques. In NAFLD, there was an inverse correlation between body weight and age and the latter independently predicted carotid findings. CONCLUSION: Cardiovascular risk in patients with FL and NAFLD needs to be assessed as a function of age and body weight.Amedeo Lonardo Silvia Lombardini Federica Scaglioni Stefano Ballestri Anna Maria Verrone Marco Bertolotti Lucia Carulli Dorval Ganazzi Nicola Carulli Paola Loria 2006World Journal of Gastroenterology2006,12,36:14
5Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms显示文摘Hepatitis C virus(HCV)infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases,which are associated with excess mortality.Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis,heart failure and stroke.In contrast,findings from studies addressing coronary artery disease and HCV have yielded conflicting results.Therefore,meta-analytic reviews and prospective studies are warranted.The pathogenic mechanisms connecting HCV infection,chronic liver disease,and atherogenesis are not completely understood.However,it has been hypothesized that HCV may promote atherogenesis and its complications through several direct and indirect biological mechanisms involving HCV colonization and replication within arterial walls,liver steatosis and fibrosis,enhanced and imbalanced secretion of inflammatory cytokines,oxidative stress,endotoxemia,mixed cryoglobulinemia,perturbed cellular and humoral immunity,hyperhomocysteinemia,hypo-adiponectinaemia,insulin resistance,type 2 diabetes and other components of the metabolic syndrome.Understanding these complex mechanisms is of fundamental importance for the development of novel therapeutic approaches to prevent and to treat vascular complications in patients with chronic HCV infection.Currently,it seems that HCV clearance by interferon and ribavirin treatment significantly reduces non-liver-related mortality;moreover,interferon-based treatment appears to decrease the risk of ischemic stroke.Luigi E Adinolfi Rosa Zampino Luciano Restivo Amedeo Lonardo Barbara Guerrera Aldo Marrone Fabio Nascimbeni Anna Florio Paola Loria 2014World Journal of Gastroenterology2014,20,13:6
6Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD显示文摘Stefano Ballestri Amedeo Lonardo Dante Romagnoli Lucia Carulli Luisa Losi Christopher P. Day Paola Loria 2012Liver Int2012,,8:4
7Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio 2012Atherosclerosis2012,,2:3
8Metabolic alterations and chronic hepatitis C: treatment strategies显示文摘Luigi E Adinolfi Luciano Restivo Rosa Zampino Amedeo Lonardo Paola Loria 2011Expert Opinion on Pharmacotherapy2011,,14:3
9From NAFLD in clinical practice to answers from guidelines显示文摘Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo 2013Journal of Hepatology2013,,:3
10Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis显示文摘Luigi E. Adinolfi Luciano Restivo Rosa Zampino Barbara Guerrera Amedeo Lonardo Laura Ruggiero Francesco Riello Paola Loria Anna Florio 2012Atherosclerosis2012,,2:2
11Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD显示文摘Amedeo Lonardo Silvia Sookoian Michel Chonchol Paola Loria Giovanni Targher 2013Current Pharmaceutical Design2013,,29:2
12Potential for statins in the chemoprevention and management of hepatocellular carcinoma显示文摘Amedeo Lonardo Paola Loria 2012J Gastroenterol Hepatol2012,,11:1
13Prevalence rates of gallstone disease in Italy显示文摘Paola Loria Michele A. Dilengite Mara Bozzoli Francesca Carubbi Roberto Messora Romano Sassatelli Marco Bertolotti Auro Tampieri Pier Luigi Tartoni Mariateresa Cassinadri Mario Delia Ciana Maurizio Contemori Nicola Save Bruno Sordi ulio Alimenti brizio Fa 1994European Journal of Epidemiology1994,,2:1
14Metabolic alterations and chronic hepatitis C: treatment strategies显示文摘Luigi E Adinolfi Luciano Restivo Rosa Zampino Amedeo Lonardo Paola Loria 2011Expert Opinion on Pharmacotherapy2011,,14:1
15Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?显示文摘Lucia Carulli Stefano Ballestri Amedeo Lonardo Francesca Lami Enrico Violi Luisa Losi Lisa Bonilauri Anna Maria Verrone Maria Rosaria Odoardi Federica Scaglioni Marco Bertolotti Paola Loria 2013Internal and Emergency Medicine2013,,4:1
16Prevalence rates of gallstone disease in Italy显示文摘Paola Loria Michele A. Dilengite Mara Bozzoli Francesca Carubbi Roberto Messora Romano Sassatelli Marco Bertolotti Auro Tampieri Pier Luigi Tartoni Mariateresa Cassinadri Mario Delia Ciana Maurizio Contemori Nicola Save Bruno Sordi ulio Alimenti brizio Fa 1994European Journal of Epidemiology1994,,2:1
17Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD)显示文摘Federica Scaglioni Mariano Marino Stefania Ciccia Alessia Procaccini M. Busacchi Paola Loria Amedeo Lonardo Marcella Malavolti Nino Carlo Battistini Massimo Pellegrini Francesca Carubbi Stefano Bellentani 2012Clinics and Research in Hepatology and Gastroenterology2012,,:1
18Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD显示文摘Lucia Carulli Mauro Maurantonio Lionel Hebbard Enrica Baldelli Paola Loria Jacob George 2013Current Pharmaceutical Design2013,,29:1
19From NAFLD in clinical practice to answers from guidelines<!-- Doctopic: Review -->显示文摘Fabio Nascimbeni Raluca Pais Stefano Bellentani Christopher Paul Day Vlad Ratziu Paola Loria Amedeo Lonardo 2013Journal of Hepatology2013,,:1
20Potential for statins in the chemoprevention and management of hepatocellular carcinoma显示文摘Amedeo Lonardo Paola Loria 2012J Gastroenterol Hepatol2012,,11:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费